When cancer becomes metastatic, it becomes an advanced stage cancer that is most often difficult to treat because the cancer becomes unresponsive to typical treatment.

Like metastatic breast cancer that becomes unresponsive to two chemotherapy treatments that include an anthracycline (such as doxorubicin or epirubicin) and a taxane (such as paclitaxel or docetaxel).

This is where new anti-cancer treatment Ixempra comes in that is recently approved by the FDA.

The approval of Ixempra includes the following:

• for use in combination with another cancer drug (capecitabine) in patients who no longer benefit from two other chemotherapy treatments: including an anthracycline (such as doxorubicin or epirubicin) and a taxane (such as paclitaxel or docetaxel
• for use alone in patients who no longer benefit from an anthracycline, a taxane and capecitabine

According to Douglas C. Throckmorton, M.D., deputy director of the FDA’s Center for Drug Evaluation and Research:

“This approval is important because it provides certain patients with a new chemotherapy option in instances where other drugs have failed.

FDA is working every day to support the development of safe and effective new therapies that benefit patients in need.”

Ixempra, a product of Bristol-Myers Squibb (BMS)  is administered by intravenous infusion.

Find more details from the FDA News and the BMS press release.

Post from: Blisstree

Ixempra: New Metastatic Breast Cancer Treatment Approved by the FDA